BSX
NYSE · Healthcare · Medical - Devices · US
Research · Oct 29, 2026
Boston Scientific (BSX) Q3 2026: U.S. Electrophysiology Sales Turn Lower
Boston Scientific's Q3 2026 sales rose 1.5% as cyber losses went unrecovered and U.S. EP fell 8%; next-gen products slipped to 2028 and full-year guidance was cut.
Research · Oct 17, 2026
[BSX] Boston Scientific: Q3 2026 earnings preview on cyber outage recovery and Watchman
Boston Scientific grew Q2 2026 sales 7.5% to $5.44 billion before an August cyberattack halted shipping; Q3 results show how much lost revenue returns in Q4.
Research · Sep 3, 2026
[BSX] Boston Scientific Thesis 2026: FARAPULSE PFA Defense + Watchman Compounding Anchor Industry-Leading Growth
Boston Scientific FY2025 revenue ~$17.7B (+14-16% organic — industry-leading large-cap medtech growth) with adj. operating margin ~28%. FARAPULSE pulsed field ablation (PFA) ramped from $720M FY2024 (Year 1 post Dec 2023 FDA approval) to $1.7-2.0B FY2025 — fastest medtech product launch in BSX history. Watchman LAA franchise reached $1.7B (+18-22% growth, ~90% market share). Axonics sacral neuromodulation acquired Nov 2024 for ~$3.7B added urology cross-sell. FY2026 thesis: FARAPULSE share defense (50%+ market share) against entering competitive PFA systems (J&J Varipulse / Medtronic PulseSelect / Abbott Volt); Watchman continued 18-22% growth on procedure volume expansion; Axonics integration cross-sell synergies; tuck-in M&A continuing; key risks: PFA competitive ramp faster than expected, Watchman growth deceleration on Abbott Amulet share, integration challenges.